US2005043218A1PendingUtilityA1

Inhibitor of stem cell proliferation and uses thereof

65
Assignee: WELLSTAT THERAPEUTICS CORPPriority: Mar 31, 1993Filed: Jul 23, 2004Published: Feb 24, 2005
Est. expiryMar 31, 2013(expired)· nominal 20-yr term from priority
Inventors:Irena TsyrlovaStephen D. Wolpe
C07K 14/4703C07K 14/805A61K 38/42C07K 14/475C07K 14/52
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed and claimed are methods for the isolation and use of stem cell inhibiting factors for regulating the abnormal stem cell cycle and for accelerating the post-chemotherapy peripheral blood cell recovery. Also disclosed and claimed are the inhibitors of stem cell proliferation.

Claims

exact text as granted — not AI-modified
1 - 46 . (canceled).  
     
     
         47 . A method of conducting gene therapy in a mammal comprising: 
 (a) removing hematopoietic cells from said mammal,    (b) transfecting said hematopoietic cells,    (c) contacting said transfected hematopoietic cells ex vivo with INPROL, wherein said INPROL is selected from the group consisting of alpha-chain of hemoglobin, beta-chain of hemoglobin, gamma-chain of hemoglobin, delta-chain of hemoglobin, epsioln-chain of hemoglobin, zeta-chain of hemoglobin, SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14; and    (d) transplanting into said mammal the hematopoietic cells of step (c).    
     
     
         48 . The method of  claim 47  further comprising after step (a) treating said hematopoietic cells with at least one stimulatory cytokine to induce stem cell proliferation.  
     
     
         49 . The method of  claim 47  further comprising after step (d) treating the mammal in vivo in INPROL.  
     
     
         50 . The method of  claim 47  wherein said INPROL is SEQ ID NO:1.  
     
     
         51 . The method of  claim 47  wherein said INPROL is SEQ ID NO:2.  
     
     
         52 . The method of  claim 47  wherein said INPROL is SEQ ID NO:3.  
     
     
         53 . The method of  claim 47  wherein said INPROL is SEQ ID NO:4.  
     
     
         54 . The method of  claim 47  wherein said INPROL is SEQ ID NO:5.  
     
     
         55 . The method of  claim 47  wherein said INPROL is SEQ ID NO:6.  
     
     
         56 . The method of  claim 47  wherein said INPROL is SEQ ID NO:7.  
     
     
         57 . The method of  claim 47  wherein said INPROL is SEQ ID NO:8.  
     
     
         58 . The method of  claim 47  wherein said INPROL is SEQ ID NO:9.  
     
     
         59 . The method of  claim 47  wherein said INPROL is SEQ ID NO:10.  
     
     
         60 . The method of  claim 47  wherein said INPROL is SEQ ID NO:11.  
     
     
         61 . The method of  claim 47  wherein said INPROL is SEQ ID NO:12.  
     
     
         62 . The method of  claim 47  wherein said INPROL is SEQ ID NO:13.  
     
     
         63 . The method of  claim 47  wherein said INPROL is SEQ ID NO:14.  
     
     
         64 . A method for conducting ex vivo stem cell expansion comprising contacting hematopoietic cells with INPROL and at least one stimulatory cytokine, wherein said INPROL is selected from the group consisting of alpha-chain of hemoglobin, beta-chain of hemoglobin, gamma-chain of hemoglobin, delta-chain of hemoglobin, epsilon-chain of hemoglobin, zeta-chain of hemoglobin, SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.  
     
     
         65 . The method of  claim 64  wherein said hematopoietic cells are cells selected from the group consisting of bone marrow cells, umbilical cord cells and peripheral blood cells.  
     
     
         66 . The method of  claim 64 , wherein said hematopoietic cells are mobilized peripheral blood cells.  
     
     
         67 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.